Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HP518 |
Synonyms | |
Therapy Description |
HP518 is a proteolysis-targeted chimera (PROTAC) that induces degradation of wild-type and mutant forms of the androgen receptor (AR), which potentially induces antitumor activity (J Clin Oncol 2024 42:4_suppl, 124; J Clin Oncol 42 2024 42:16_suppl, 5058). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HP518 | HP 518|HP-518 | Hormone - Anti-androgens 54 | HP518 is a proteolysis-targeted chimera (PROTAC) that induces degradation of wild-type and mutant forms of the androgen receptor (AR), which potentially induces antitumor activity (J Clin Oncol 2024 42:4_suppl, 124; J Clin Oncol 42 2024 42:16_suppl, 5058). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05252364 | Phase I | HP518 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer | Completed | AUS | 0 |